Sagimet Biosciences Inc.

SGMT

US7867001049

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 23:00:00 11/07/2024 BST			5-day change	1st Jan Change
3.33 ^USD	+1.83%		+6.39%	-38.56%

07-01	Goldman Sachs Downgrades Sagimet Biosciences to Neutral From Buy, Cuts Price Target to $6 From $23	MT
07-01	Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell Small Cap Comp Value Index	CI

Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000E Index

July 30, 2024

Latest news about Sagimet Biosciences Inc.

Goldman Sachs Downgrades Sagimet Biosciences to Neutral From Buy, Cuts Price Target to $6 From $23	07-01	MT
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell Small Cap Comp Value Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell Small Cap Completeness Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000 Value Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 2000 Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000E Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 2500 Growth Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 2500 Value Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000E Growth Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000 Growth Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 2000 Value Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 2000 Growth Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 2000 Dynamic Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 2500 Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000 Index	06-30	CI
Sagimet Biosciences Inc.(NasdaqGM:SGMT) dropped from Russell 3000E Value Index	06-30	CI
Goldman Sachs Downgrades Sagimet Biosciences to Hold From Buy, Price Target at $6	06-28	MT
Sagimet Biosciences Says Potential Fatty Liver Disease Drug Meets Endpoints in Phase 2B Trial	06-06	MT
Exchange-Traded Funds Edge Up, Equity Futures Mixed Pre-Bell Thursday as Investors Await Fresh Data	06-06	MT
Sagimet Biosciences Inc. Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024	06-06	CI
Goldman Sachs Adjusts Price Target on Sagimet Biosciences to $23 From $27, Keeps Buy Rating	05-16	MT
Sagimet Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Sagimet Biosciences Names Thierry Chauche CFO	05-06	MT
Sagimet Biosciences Inc. Announces Executive Changes	05-06	CI

Chart Sagimet Biosciences Inc.

Duration

Period

More charts

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.

Sector

Biotechnology & Medical Research

Calendar

18/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.65 USD

Average target price

35.8 USD

Spread / Average Target

+880.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SAGIMET BIOSCIENCES INC.	-38.56%	116M
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.38%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research